Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib with Cisplatin and Radiation in HNSCC
NCT02585973Phase 1Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in head and neck squamous cell carcinoma (HNSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 7 weeks. Started Oct 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02585973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585973.